PTGFRN and thyroid gland carcinoma: Based on the FPRP value, we upgraded cumulative evidence from moderate to strong for rs7000448 in prostate cancer, weak to moderate for rs16901979, rs1447295, rs6983267, rs7017300, rs7837688, rs1016343, rs620861, rs10086908 associated with prostate cancer, rs10505477, rs6983267 with colorectal cancer, rs6983267 with thyroid cancer, and rs13281615 with breast cancer.